ULARXI Trademark

Trademark Overview

On Sunday, June 9, 2019, a trademark application was filed for ULARXI with the United States Patent and Trademark Office. The USPTO has given the ULARXI trademark a serial number of 88465338. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Monday, February 14, 2022. This trademark is owned by Pfizer Inc.. The ULARXI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use
ularxi

General Information

Serial Number88465338
Word MarkULARXI
Filing DateSunday, June 9, 2019
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateMonday, February 14, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 6, 2019

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateMonday, February 14, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Monday, February 14, 2022ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
Monday, February 14, 2022ABANDONMENT - AFTER PUBLICATION
Friday, February 11, 2022TEAS EXPRESS ABANDONMENT RECEIVED
Friday, September 3, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 1, 2021EXTENSION 4 GRANTED
Wednesday, September 1, 2021EXTENSION 4 FILED
Wednesday, September 1, 2021TEAS EXTENSION RECEIVED
Wednesday, March 3, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 1, 2021EXTENSION 3 GRANTED
Monday, March 1, 2021EXTENSION 3 FILED
Monday, March 1, 2021TEAS EXTENSION RECEIVED
Wednesday, September 2, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 31, 2020EXTENSION 2 GRANTED
Monday, August 31, 2020EXTENSION 2 FILED
Monday, August 31, 2020TEAS EXTENSION RECEIVED
Wednesday, February 26, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 24, 2020EXTENSION 1 GRANTED
Monday, February 24, 2020EXTENSION 1 FILED
Monday, February 24, 2020TEAS EXTENSION RECEIVED
Monday, February 24, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, February 24, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, February 21, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, February 21, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, February 21, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, February 21, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, February 21, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, October 1, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 6, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 6, 2019PUBLISHED FOR OPPOSITION
Wednesday, July 17, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Saturday, June 22, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, June 22, 2019ASSIGNED TO EXAMINER
Friday, June 21, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Wednesday, June 12, 2019NEW APPLICATION ENTERED IN TRAM

Related Keywords

ularxi preparations disorders pharmaceutical dysfunction treatment liver erectile blood viral urological